Barrett's esophagus screening: Difference between revisions
Usama Talib (talk | contribs) No edit summary |
Usama Talib (talk | contribs) |
||
| Line 14: | Line 14: | ||
Weak recommendation, moderate-quality [[evidence]]: | Weak recommendation, moderate-quality [[evidence]]: | ||
* [[Endoscopic]] surveillance in [[patients]] with [[Barrett's esophagus]] .The following intervals are recommended: | * [[Endoscopic]] surveillance in [[patients]] with [[Barrett's esophagus]]. The following intervals are recommended: | ||
** No [[dysplasia]]: 3–5 years. | ** No [[dysplasia]]: 3–5 years. | ||
** Low-grade [[dysplasia]]: 6–12 months. | ** Low-grade [[dysplasia]]: 6–12 months. | ||
** High-grade [[dysplasia]] in the absence of eradication [[therapy]]: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | ** High-grade [[dysplasia]] in the absence of eradication [[therapy]]: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | ||
Revision as of 19:00, 6 February 2018
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus screening On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus screening |
|
Risk calculators and risk factors for Barrett's esophagus screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amresh Kumar MD [2]
Overview
Barrett's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dysplasia. Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma: Age > 50 years old, male, white, chronic GERD, hiatal hernia, elevated BMI (body mass index), and intra-abdominal distribution of body fat. Strong recommendation, low-quality evidence against screening general population with GERD and no risk factors.
Screening
- Barrett's esophagus is a major risk factor for development of esophageal adenocarcinoma[1][2][3][4][5].
- After diagnosis, regular surveillance is needed based on the grade of dysplasia.
- Strong recommendation, low-quality evidence against screening general population with GERD and no risk factors.[6]
Weak recommendation, moderate-quality evidence:
- Endoscopic surveillance in patients with Barrett's esophagus. The following intervals are recommended:
References
- ↑ Drewitz DJ, Sampliner RE, Garewal HS (1997). "The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years". Am J Gastroenterol. 92 (2): 212–5. PMID 9040193.
- ↑ Eckardt VF, Kanzler G, Bernhard G (2001). "Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation". Am J Med. 111 (1): 33–7. PMID 11448658.
- ↑ Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P (2008). "Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis". Gastrointest Endosc. 67 (3): 394–8. doi:10.1016/j.gie.2007.07.019. PMID 18045592.
- ↑ Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE (2006). "Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus". Clin Gastroenterol Hepatol. 4 (5): 566–72. doi:10.1016/j.cgh.2006.03.001. PMID 16630761.
- ↑ Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S; et al. (2012). "The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis". Gut. 61 (7): 970–6. doi:10.1136/gutjnl-2011-300730. PMID 21997553.
- ↑ 6.0 6.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. Unknown parameter
|month=ignored (help)